Table 1.
Analysis of clinical characteristics associated with overall survival and chemotherapy response in advanced NSCLC patients
| Characteristics | No of cases | 2-year survival rate (%) | ORR P-value | OS P-value |
|---|---|---|---|---|
| Sex | 0.527 | 0.438 | ||
| Male | 74 | 17.6 | ||
| Female | 38 | 26.3 | ||
| Age (years) | 0.396 | 0.798 | ||
| ≤60 | 52 | 19.2 | ||
| >60 | 60 | 21.7 | ||
| TNM classification | 0.067 | 0.788 | ||
| III | 27 | 11.1 | ||
| IV | 85 | 23.5 | ||
| Smoking | 0.658 | 0.313 | ||
| Yes | 51 | 23.5 | ||
| No | 61 | 18.0 | ||
| Histology | 0.301 | 0.906 | ||
| SQ | 34 | 17.6 | ||
| AC | 78 | 21.8 | ||
| Chemotherapy regimen | 0.195 | 0.504 | ||
| GP | 53 | 15.1 | ||
| TP | 28 | 25.0 | ||
| NP | 31 | 25.8 |
Abbreviations: AC, adenocarcinoma; GP, gemcitabine plus cisplatin; NP, vinorelbine plus cisplatin; NSCLC, non-small-cell lung cancer; ORR, overall response; OS, overall survival; SQ, squamous cell carcinoma; TNM, tumor node metastasis; TP, paclitaxel plus cisplatin.